Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | MGAM | O43451 | 1/20 | 0.46 |
| ▸ | SI | P14410 | 1/20 | 0.46 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 4/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20599735 | 0.91 | TP53 (0.43) | GAAMGAMSIMGAM2TSHR | |
| SCHEMBL21987187 | 0.91 | TP53 (0.43) | GAAMGAMSIMGAM2TSHR | |
| SCHEMBL1017827 | 0.91 | MGAM (0.42) | GAAMGAMSIMGAM2TSHR | |
| SCHEMBL1013082 | 0.91 | EPHX2 (0.43) | GAAMGAMSIMGAM2TSHR | |
| SCHEMBL6710648 | 0.89 | GAA (0.41) | GAAMGAMSIMGAM2TSHR | |
| SCHEMBL1014784 | 0.89 | EPHX2 (0.46) | GAAMGAMSIMGAM2TSHR | |
| SCHEMBL17525561 | 0.89 | EPHX2 (0.46) | GAAMGAMSIMGAM2TSHR | |
| SCHEMBL20599527 | 0.86 | SMN1; SMN2 (0.45) | GAAMGAMSIMGAM2SMN1; SMN2 | |
| SCHEMBL3594828 | 0.85 | GLA (0.39) | GAAMGAMSIMGAM2TSHR | |
| SCHEMBL20599690 | 0.83 | CHRNB2 (0.40) | GAAMGAMSIMGAM2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 791 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2387561-A2 | IMPROVED PROCESS FOR THE PREPARATION OF HIGHLY PURE (3R,5S)-7-Ý2-CYCLOPROPYL-4-(4-FLUOROPHENYL) QUINOLIN-3-YL¨-3,5-DIHYDROXY-6(E)-HEPTENOIC ACID AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | MSN Laboratories Limited (IN) | 2011-11-23 | — | — | EP | claimed |
| WO-2010089770-A2 | IMPROVED PROCESS FOR THE PREPARATION OF HIGHLY PURE (3R,5S)-7-[2-CYCLOPROPYL-4-(4-FLUOROPHENYL) QUINOLIN-3-YL]-3,5-DIHYDROXY-6(E)-HEPTENOIC ACID AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | MSN LABORATORIES LIMITED (IN) | 2010-08-12 | — | — | WO | claimed |
| EP-1261657-B1 | POLY(3-CYCLOPROPYL-3-HYDROXYPROPIONATE) AND PROCESSES FOR ITS PREPARATION AND DERIVATIVES THEREOF | EASTMAN CHEM CO (US) | 2004-11-10 | — | — | EP | claimed |
| US-20030212294-A1 | Poly(3-cyclopropyl-3-hydroxypropionate) and processes for its preparation and derivatives thereof | HUBBS JOHN CLARK (US) | 2003-11-13 | — | — | US | claimed |
| US-20030208092-A1 | Poly(3-cyclopropyl-3-hydroxypropionate) and processes for its preparation and derivatives thereof | HUBBS JOHN CLARK (US) | 2003-11-06 | — | — | US | claimed |
| JP-2003518519-A | — | — | 2003-06-10 | — | — | JP | claimed |
| EP-1261657-A2 | POLY(3-CYCLOPROPYL-3-HYDROXYPROPIONATE) AND PROCESSES FOR ITS PREPARATION AND DERIVATIVES THEREOF | EASTMAN CHEMICAL COMPANY (US) | 2002-12-04 | — | — | EP | claimed |
| US-6441176-B1 | N-(5-CYCLOPROPYL-1-QUINOLIN-5-YL-1H-PYRAZOLE-4-CARBONYL) -GUANIDINE; REACTING QUINOLIN-5-YL-HYDRAZINE AND METHYL-3-CYCLOPROPYL-2-DIMETHYLENAMINO-3-OXOPROPANOATE, HYDROYLZING, FORMING ACYLHALIDE AND FURTHER REACTING WITH GUANIDINE | PFIZER INC. | 2002-08-27 | — | — | US | claimed |
| EP-1101763-A2 | Method for preparing sodium-hydrogen exchanger type 1 inhibitor | Pfizer Products Inc. (US) | 2001-05-23 | — | — | EP | claimed |
| WO-2000068290-A2 | POLY(3-CYCLOPROPYL-3-HYDROXYPROPIONATE) AND PROCESSES FOR ITS PREPARATION AND DERIVATIVES THEREOF | EASTMAN CHEMICAL COMPANY (US) | 2000-11-16 | — | — | WO | claimed |
| EP-4744661-A2 | NOVEL PYRIMIDIN-2-YL SULFONAMIDE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2026-05-20 | — | — | EP | disclosed |
| EP-4731262-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A QUINAZOLINE COMPOUND | Astellas Pharma Inc. (JP) | 2026-04-29 | — | — | EP | disclosed |
| US-12611401-B2 | Combinations comprising benzodioxol as GLP-1R agonists for use in the treatment of NASH/NAFLD and related diseases | PFIZER INC. (US) | 2026-04-28 | — | — | US | disclosed |
| US-20260070896-A1 | HETEROCYCLE DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | UNIV LEUVEN KATH (BE) | 2026-03-12 | — | — | US | disclosed |
| US-12570666-B2 | Furoindazole derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2026-03-10 | — | — | US | disclosed |
| WO-1998052944-A1 | HETEROARYLCARBOXAMIDE COMPOUNDS ACTIVE AGAINST PROTEIN TYROSINE KINASE RELATED DISORDERS | SUGEN, INC. (US) | 1998-11-26 | — | — | WO | disclosed |
| EP-0378850-B1 | Substituted pyrido(2,3-d) pyrimidines | BAYER AG (DE) | 1994-04-06 | — | — | EP | disclosed |
| US-5145959-A | Enzyme inhibitors; antilipemic agents; treatment of atherosclerosis | BAYER AKTIENGESELLSCHAFT (DE) | 1992-09-08 | — | — | US | disclosed |
| US-5075311-A | Anticholesterol agents | BAYER AKTIENGESELLSCHAFT (DE) | 1991-12-24 | — | — | US | disclosed |
| US-4829076-A | CARDIOVASCULAR DISORDERS | ALKALOIDA VEGYESZETI GYAR (HU) | 1989-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212294-A1 | Poly(3-cyclopropyl-3-hydroxypropionate) and processes for its preparation and derivatives thereof | HACL2, HPD, GRHPR | GAA 1126/4885MGAM 592/4885SI 72/4885 |
| US-20030208092-A1 | Poly(3-cyclopropyl-3-hydroxypropionate) and processes for its preparation and derivatives thereof | HPD, HACL2, GRHPR | GAA 1073/4885MGAM 625/4885SI 69/4885 |
| US-12570666-B2 | Furoindazole derivatives | FURIN, CYP2F1, CYP3A7 | GAA 599/4885MGAM 2228/4885SI 555/4885 |
| US-12611401-B2 | Combinations comprising benzodioxol as GLP-1R agonists for use in the treatment of NASH/NAFLD and related diseases | GLP1R, GCKR, GPR119 | GAA 973/4885MGAM 3303/4885SI 2991/4885 |
| US-20260070896-A1 | HETEROCYCLE DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | TRPM6, TRPV3, TRPM2 | GAA 4364/4885MGAM 4372/4885SI 3379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.